Tìm theo
Apixaban
Các tên gọi khác (5 ) :
  • Apixabanum
  • BMS 562247-01
  • BMS-562247
  • BMS-562247-01
  • Eliquis
Thuốc Gốc
Small Molecule
CAS: 503612-47-3
ATC: B01AF02
CTHH: C25H25N5O4
PTK: 459.4971
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor (of both free and prothrombinase-bound FXa independently of antithrombin III) for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. FDA approved on December 28, 2012.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C25H25N5O4
Phân tử khối
459.4971
Monoisotopic mass
459.190654313
InChI
InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)
InChI Key
InChIKey=QNZCBYKSOIHPEH-UHFFFAOYSA-N
IUPAC Name
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridine-3-carboxamide
Traditional IUPAC Name
apixaban
SMILES
COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O
Độ hòa tan
Aqueous solubility: 40-50 μg/ml in 0.9% saline solution
logP
1.83
logS
-3.8
pKa (strongest acidic)
13.12
pKa (Strongest Basic)
-1.6
PSA
110.76 Å2
Refractivity
126.9 m3·mol-1
Polarizability
49.62 Å3
Rotatable Bond Count
5
H Bond Acceptor Count
5
H Bond Donor Count
1
Physiological Charge
0
Number of Rings
5
Bioavailability
1
Rule of Five
true
Ghose Filter
true
Dược Lực Học : Apixaban acts by inhibiting coagulation, and thus prevents development of blood clots. As a result of FXa inhibition, apixaban prolongs clotting tests such as prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT). Changes observed in these clotting tests at the expected therapeutic dose, however, are small, subject to a high degree of variability, and not useful in monitoring the anticoagulation effect of apixaban. The Rotachrom® Heparin chromogenic assay is not recommended for assessing the anticoagulant effect of apixaban.
Cơ Chế Tác Dụng : Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor (of both free and prothrombinase-bound FXa independently of antithrombin III) for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. FDA approved on December 28, 2012. Apixaban acts by directly inhibiting, in a reversible manner, free and clot-bound factor Xa to inhibit coagulation.
Dược Động Học :
▧ Absorption :
Apixaban is absorbed in the stomach and small intestine. For doses up to 10 mg, the absolute bioavailability is about 50%. For oral administration, absorption is not affected by the presence of food, and it takes about 3-4 hours to achieve maximum plasma concentrations. For large oral doses equal or greater than 25 mg, absorption is dissolution limited and bioavailability is decreased. Most of the absorption occurs in the distal small intestine and the ascending colon.
▧ Volume of Distribution :
The steady state volume of distribution is 21 L.
▧ Protein binding :
Apixaban is about 87% plasma protein bound.
▧ Metabolism :
Apixaban mainly undergoes o-demethylation and hydroxylation to metabolites. The major site of biotransformation is at the 3-oxopiperidinyl moiety. The main enzyme responsible for metabolism is CYP3A4/5 while CYP1A2, 2C8, 2C9, 2C19, and 2J2 are minor metabolic enzymes. There are no active metabolites and unchanged apixaban is the primary circulating entity.
▧ Route of Elimination :
25% of the administered dose is eliminated in the feces and urine. For elimination in the feces, it is excreted by the intestine and bile to the feces.
▧ Half Life :
If administered orally, the half life is 12 hours (due to prolonged absorption). If administerd by I.V., the half-life is about 5 hours.
▧ Clearance :
About 27% of total apixaban is renally cleared.
Độc Tính : Major bleeding events.
Chỉ Định : Apixaban is to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It has also been used to lower the risk of developing venous thrombosis post-orthopedic surgical procedures.
Tương Tác Thuốc :
  • Dabigatran etexilate Concomitant therapy with another anticoagulant may increase bleed risk. Monitor closely for adverse effects.
  • Enoxaparin Due to pharmacodynamic interaction, a 50-60% increase in anti-Factor Xa activity may be observed with concomitant therapy.
  • Eptifibatide Monitor therapy due to potential risk of bleeding.
  • Etravirine Apixaban, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. Concomitant use should be avoided.
  • Itraconazole Avoid combination. Otherwise, itraconazole will likely increase apixaban serum concentration.
  • Ketoconazole Avoid combination. Otherwise, ketoconazole will likely increase apixaban serum concentration.
  • Naproxen Due to pharmacodynamic interaction, a 50-60% increase in anti-Factor Xa activity may be observed with concomitant therapy.
  • Posaconazole Avoid combination. Otherwise, posaconazole will likely increase apixaban serum concentration.
  • Ritonavir Avoid combination. Otherwise, ritonavir will likely increase apixaban serum concentration.
  • Rivaroxaban Avoid combination. Otherwise, excessive anticoagulation will likely occur.
  • Voriconazole Avoid combination. Otherwise, voriconazole will likely increase apixaban serum concentration.
Liều Lượng & Cách Dùng : Tablet - Oral - 2.5 mg
Tablet - Oral - 5 mg
Dữ Kiện Thương Mại
Nhà Sản Xuất
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB06605
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=10182969
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D03213
ChemSpider
http://www.chemspider.com/Chemical-Structure.8358471.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=19023
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0003-0894-21
Wikipedia
http://en.wikipedia.org/wiki/Apixaban
RxList
http://www.rxlist.com/eliquis-drug.htm
Drugs.com
http://www.drugs.com/eliquis.html
... loading
... loading